Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

NCT ID: NCT01809847

Last Updated: 2016-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2015-01-31

Brief Summary

To study the safety and efficacy of anti-CD20 blockade with ofatumumab in the context of allogeneic HCT in CLL

Detailed Description

The goal of the study is to investigate the safety and efficacy of a consequent anti-CD20 therapy with the antibody ofatumumab in the context of allogeneic HCT. Allogeneic HCT itself is not a study intervention and is triggered by the availability of an HLA-compatible stem cell donor. The study is divided into an induction part and a maintenance part. During induction where the antibody is combined with high dose dexamethasone, the main goal is to reduce the tumor load prior to allogeneic HCT. Patients who achieved disease control (CR, PR and SD) by the antibody proceed to maintenance therapy with the antibody. Patients with progressive disease go off study. The idea behind maintenance therapy is that ofatumumab may contribute to tumor control early after allogeneic stem cell transplantation while T-cell based graft-versus leukemia effects are still not fully established. External tumor control could lower the pressure to taper immunosuppressive drugs early after transplantation and could thereby indirectly contribute to better GVHD-prophylaxis. Furthermore, anti-CD20 antibodies have proven activity in the treatment of chronic GVHD. In summary, the concept of a consequent CD20 blockade in the context of allogeneic transplantation could result in better leukemic control and better GVHD prophylaxis, which is a highly attractive goal.

Conditions

Chronic Lymphatic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ofatumumab

First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.

Group Type: EXPERIMENTAL

Ofatumumab

Intervention Type: DRUG

Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.

An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.

Interventions

Ofatumumab

Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.

An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.

Intervention Type: DRUG

Other Intervention Names

Arzerra; Anti-CD20 antibody

Eligibility Criteria

Inclusion Criteria

• Diagnosis of CLL according to WHO criteria (Hallek 2008) confirmed by flow cytometry of peripheral blood or bone marrow
• Age > 55 years
• Poor-risk disease according to the EBMT CLL Transplant Consensus

• Non-response or early relapse (within 12 months) after purine analogue-containing therapy
• Relapse (within 24 months) after purine analogue combination therapy or treatment of similar efficacy (ie, autologous stem cell transplantation)
• p53 deletion/mutation (del 17p-) requiring treatment
• Measurable disease in the peripheral blood defined by a minimum clonal lymphocyte count of 0.5 GPT/L at the time of study inclusion
• Medically fit patients eligible for allogeneic HCT
• Informed consent for related and unrelated donor search and the goal to perform allogeneic HCT
• Sexually mature males must agree to use adequate and medically accepted method of contraception throughout the study if their sexual partners are woman of child bearing potential (WOCBP) WOCBP must be using an adequate and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 3 months after the study.
• WOCBP includes any female that has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >12 consecutive months); or woman on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35mlU/mL.
• WOCBP must have a negative serum or urine pregnancy test prior to the start of the study.

Exclusion Criteria

• Richter's transformation in current relapse or active disease
• Prior allogeneic HCT
• Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or participation in any other interventional clinical study
• Non-response to monotherapy with ofatumumab prior to study inclusion
• Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (left ventricular ejection fraction < 50%)
• Abnormal renal function defined by an estimated GFR < 50 ml/min
• Abnormal lung function tests defined by a DLCO <50%, FEV1%VC <70% despite appropriate treatment
• Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg or HBcAb
• Positive serology for hepatitis C (HC) defined as a positive test for anti-HCV, confirmed by PCR
• Screening laboratory values:

• total bilirubin >1.5 times upper normal limit (unless due to AIHA or a known history of Gilbert's disease)
• ALT or AST >2.5 times upper normal limit
• Gamma glutamyl transpeptidase (GGT) >2.5 times upper normal limit (unless due to disease involvement of the liver)
• Other past or current hematologic or solid organ malignancy. Subjects who have been free of malignancy for at least 3 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
• Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
• Pregnant or lactating woman
• Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.

• Minimum Eligible Age: 56 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital Dresden

OTHER

Sponsor Role: collaborator

University Hospital Ulm

OTHER

Sponsor Role: collaborator

University Hospital Schleswig-Holstein

OTHER

Sponsor Role: collaborator

University Hospital of Cologne

OTHER

Sponsor Role: collaborator

Technische Universität Dresden

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Johannes Schetelig, PD Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, 01307 Dresden

Locations

Universitätsklinikum Heidelberg

Heidelberg, Baden-Wurttemberg, Germany

Universitätsklinikum Ulm

Ulm, Baden-Wurttemberg, Germany

Städtisches Klinikum München Schwabing

München, Bavaria, Germany

Klinikum Frankfurt (Oder) GmbH

Frankfurt (Oder), Brandenburg, Germany

Deutsche Klinik für Diagnostik

Wiesbaden, Hesse, Germany

Universitätsmedizin Göttingen

Göttingen, Lower Saxony, Germany

Klinikum der Universität zu Köln

Cologne, North Rhine-Westphalia, Germany

Universitätsklinikum Düsseldorf

Düsseldorf, North Rhine-Westphalia, Germany

Klinikum der Johannes Gutenberg Universität

Mainz, Rhineland-Palatinate, Germany

Klinikum Chemnitz GmbH

Chemnitz, Saxony, Germany

Universitätsklinikum Dresden

Dresden, Saxony, Germany

Countries

Germany

Related Links

http://www.sal-aml.org

Website Study Alliance Leukemia (coordinating study group)

Other Identifiers

2012-001947-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TUD-CLL-X4-054

Identifier Type: -

Identifier Source: org_study_id